Bank of Montreal’s Nuvectis Pharma NVCT Stock Holding History

Bank of Montreal’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,012	Closed	-$200K	–	4098
2023 Q2	$200K	Buy	+11,012	New	+$176K	﹤0.01%	3224

Other funds holding NVCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of Montreal's NVCT Position: Q3 2023 in Review

Bank of Montreal sold out of Nuvectis Pharma (NVCT) in Q3 2023, closing a stake of 11,012 shares — an estimated $200K sold.

Bank of Montreal first reported a position in NVCT in Q2 2023 and held it in 1 quarter. The position peaked at $200K in Q2 2023. 33 funds tracked by Wall St. Rank hold NVCT as of Q3 2023.

Bank of Montreal reported no remaining Nuvectis Pharma position as of Q3 2023 after selling out during the quarter.
Bank of Montreal sold 11,012 Nuvectis Pharma shares in Q3 2023, an estimated $200K.
Bank of Montreal first reported a position in Nuvectis Pharma in Q2 2023 and held it in 1 quarter.
Bank of Montreal's Nuvectis Pharma position peaked at $200K in Q2 2023.
33 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2023.

Based on Bank of Montreal's 13F filing for Q3 2023, filed 1 Nov 2023.